Standout Papers

Differential Diagnosis of Glomerular Disease: A Systematic and Inclusive Approach 2012 2026 2016 2021 3.5k
  1. Differential Diagnosis of Glomerular Disease: A Systematic and Inclusive Approach (2013)
    Lee A. Hebert, Samir M. Parikh et al. American Journal of Nephrology
  2. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study (2012)
    Brad H. Rovin, Richard Furie et al. Arthritis & Rheumatism
  3. Update on Lupus Nephritis (2016)
    Salem Almaani, Alexa Meara et al. Clinical Journal of the American Society of Nephrology
  4. Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis (2020)
    Richard Furie, Brad H. Rovin et al. New England Journal of Medicine
  5. Lupus nephritis is linked to disease-activity associated expansions and immunity to a gut commensal (2019)
    Doua F. Azzouz, Adriana Heguy et al. Annals of the Rheumatic Diseases
  6. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial (2021)
    Brad H. Rovin, Y K Onno Teng et al. The Lancet
  7. Update on Lupus Nephritis: Core Curriculum 2020 (2020)
    Samir V. Parikh, Salem Almaani et al. American Journal of Kidney Diseases
  8. B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial (2022)
    Richard Furie, Gustavo Aroca et al. Annals of the Rheumatic Diseases
  9. Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis (2022)
    David Jayne, Brad H. Rovin et al. Annals of the Rheumatic Diseases
  10. Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial (2023)
    Richard Lafayette, Jens Kristensen et al. The Lancet
  11. KDIGO 2024 Clinical Practice Guideline for the management of LUPUS NEPHRITIS (2024)
    Brad H. Rovin, Isabelle Ayoub et al. Kidney International
  12. KDIGO 2024 Clinical Practice Guideline for the Management of Antineutrophil Cytoplasmic Antibody (ANCA)–Associated Vasculitis (2024)
    Jürgen Floege, David Jayne et al. Kidney International

Immediate Impact

1 by Nobel laureates 13 from Science/Nature 64 standout
Sub-graph 1 of 22

Citing Papers

edgeR v4: powerful differential analysis of sequencing data with expanded functionality and improved support for small counts and larger datasets
2025 Standout
Systemic Lupus Erythematosus
2024 Standout
6 intermediate papers

Works of Brad H. Rovin being referenced

KDIGO 2024 Clinical Practice Guideline for the management of LUPUS NEPHRITIS
2024 Standout
Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
2021 Standout
and 7 more

Author Peers

Author Last Decade Papers Cites
Brad H. Rovin 7075 7512 5777 338 18.7k
Hans‐Joachim Anders 7900 3924 9349 412 24.8k
David A. Roth 6488 3304 2271 208 20.2k
Tak Mao Chan 4656 4284 2966 424 12.8k
Gerald B. Appel 7794 4761 3171 202 13.1k
William G. Couser 8122 1951 3559 216 15.4k
Claudio Ponticelli 7480 3099 1923 451 15.8k
Yasuhiko Tomino 10755 1537 2906 622 19.3k
Lee A. Hebert 4673 2550 2173 147 10.7k
Takashi Wada 2825 1407 2779 442 13.1k
Xueqing Yu 5071 1667 1652 347 11.8k

All Works

Loading papers...

Rankless by CCL
2026